Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial

OBJECTIVE: To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19. DESIGN: CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. SETTING: 17 hospital sites in India and Aus...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardine, Meg J, Kotwal, Sradha S, Bassi, Abhinav, Hockham, Carinna, Jones, Mark, Wilcox, Arlen, Pollock, Carol, Burrell, Louise M, McGree, James, Rathore, Vinay, Jenkins, Christine R, Gupta, Lalit, Ritchie, Angus, Bangi, Ashpak, D’Cruz, Sanjay, McLachlan, Andrew J, Finfer, Simon, Cummins, Michelle M, Snelling, Thomas, Jha, Vivekanand, Bhalla, Ashish, Fox, Gregory, Nag, Santosh Kumar, Makris, Angela, Mangos, George, Post, Jeffrey, Rao, Indu Ramachandra, Sukkar, Louisa, Sullivan, Richard, Di Tanna, Gian Luca, Trubiano, Jason, Zoungas, Sophia, Bains, Lovenish, Jindal, Atul, Nagarkar, Nitin M, Nayak, Saurabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667467/
https://www.ncbi.nlm.nih.gov/pubmed/36384746
http://dx.doi.org/10.1136/bmj-2022-072175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667467/
https://www.ncbi.nlm.nih.gov/pubmed/36384746
http://dx.doi.org/10.1136/bmj-2022-072175

Ejemplares similares